Clene Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLNN research report →
Range $50 – $50
Price Chart
About the company
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies.
- CEO
- Robert Etherington
- IPO
- 2018
- Employees
- 78
- HQ
- Salt Lake City, UT, US
Get TickerSpark's AI analysis on CLNN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $50.69M
- P/E
- -1.41
- Fwd P/E
- 1.67
- PEG
- -0.08
- P/S
- 204.81
- P/B
- 0.00
- EV/EBITDA
- -2.36
- Div Yield
- 0.00%
- Gross Margin
- -80.67%
- Op Margin
- -8823.11%
- Net Margin
- -11271.43%
- ROE
- 175.40%
- ROIC
- -111.79%
Latest fiscal year · YoY change
- Revenue
- $200.00K-41.5%
- Gross Profit
- $157.00K-42.3%
- Op Income
- $-23,083,000
- Net Income
- $-26,173,000+33.6%
- EPS
- $-2.65+53.3%
- OCF Growth
- +13.0%
- FCF Growth
- +12.9%
- 52W High
- $10.84
- 52W Low
- $3.02
- 50D MA
- $3.87
- 200D MA
- $5.12
- Beta
- 0.92
- RSI (14)
- 43
- Avg Volume
- 115.06K
No earnings-call transcripts are available for CLNN yet.
- Free Float
- 79.6%
- Shares Outstanding
- 14.40M
- Float Shares
- 11.46M
of shares held by institutions
33 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Empery Asset Management, LP | 916.53K | ▲ 916.53K |
| Scoggin Management LP | 600.00K | ▲ 300.00K |
| Boxer Capital Management, LLC | 477.51K | 0 |
| Vanguard Capital Management LLC | 333.41K | ▼ 300 |
| Ensign Peak Advisors, Inc | 321.46K | ▼ 26.60K |
| Vanguard Group Inc | 222.91K | ▲ 21.93K |
| Geode Capital Management, LLC | 112.57K | ▲ 10.35K |
| Vanguard Fiduciary Trust Co | 73.01K | ▲ 15.24K |
| Blackrock, Inc. | 67.55K | ▲ 5.99K |
| State Street Corp | 37.90K | ▲ 8.10K |
| Parsons Capital Management Inc/Ri | 37.24K | 0 |
| Peak6 LLC | 30.01K | 0 |
Held by 22 ETFs
Biggest fund positions in CLNN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | WILCOX REED N | buy | 2,000 |
| Nov 18, 26 | WILCOX REED N | buy | 8,000 |
| Nov 12, 26 | Desai Arjun JJ | other | 3,549 |
| Nov 12, 26 | Jacobovitz Shalom | other | 4,591 |
| Nov 12, 26 | Mosca Alison | other | 4,707 |
| Nov 12, 26 | Kiernan Matthew | other | 3,086 |
| Nov 12, 26 | MATLIN DAVID J | other | 6,019 |
| Nov 12, 26 | Gay Jonathon | other | 3,665 |
| Nov 12, 26 | McLaughlin Vallerie | other | 3,395 |
| Nov 12, 26 | WILCOX REED N | other | 3,395 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLNN coverage
Recent articles, reports, and earnings notes.
No research on CLNN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLNN report →Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application
businesswire.com · Nov 12
Clene Inc. (CLNN) Tops Q3 Earnings Estimates
zacks.com · Nov 4
Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights
globenewswire.com · Nov 4
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
globenewswire.com · Oct 19
Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN)
defenseworld.net · Oct 19
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision
marketbeat.com · Oct 2
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of “Moderate Buy” from Brokerages
defenseworld.net · Sep 30
Clene to Present at Upcoming Investor Conferences
globenewswire.com · Sep 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.